scispace - formally typeset
Open AccessJournal ArticleDOI

Artemisinin Resistance in Plasmodium falciparum Malaria

Reads0
Chats0
TLDR
The overall median clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours in Wang Pha (P<0.001) in each of the two locations as discussed by the authors.
Abstract
We studied 40 patients in each of the two locations. The overall median parasite clearance times were 84 hours (interquartile range, 60 to 96) in Pailin and 48 hours (interquartile range, 36 to 66) in Wang Pha (P<0.001). Recrudescence confirmed by means of polymerase-chain-reaction assay occurred in 6 of 20 patients (30%) receiving artesunate monotherapy and 1 of 20 (5%) receiving artesunate–mefloquine therapy in Pailin, as compared with 2 of 20 (10%) and 1 of 20 (5%), respectively, in Wang Pha (P = 0. 31). These markedly different parasitologic responses were not explained by differences in age, artesunate or dihydroartemisinin pharmacokinetics, results of isotopic in vitro sensitivity tests, or putative molecular correlates of P. falciparum drug resistance (mutations or amplifications of the gene encoding a multidrug resistance protein [PfMDR1] or mutations in the gene encoding sarco–endoplasmic reticulum calcium ATPase6 [PfSERCA]). Adverse events were mild and did not differ significantly between the two treatment groups. CONCLUSIONS P. falciparum has reduced in vivo susceptibility to artesunate in western Cambodia as compared with northwestern Thailand. Resistance is characterized by slow parasite clearance in vivo without corresponding reductions on conventional in vitro susceptibility testing. Containment measures are urgently needed. (ClinicalTrials.gov number, NCT00493363, and Current Controlled Trials number, ISRCTN64835265.)

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Artemisinin-induced parasite dormancy: a plausible mechanism for treatment failure.

TL;DR: Support is added for the dormancy recovery hypothesis for P. falciparum malaria, highlighting the potential role of this parasite sub-population in treatment failure following monotherapy and reinforcing the importance of using ART in combination with other anti-malarials.
Journal ArticleDOI

Control of malaria and other vector-borne protozoan diseases in the tropics: enduring challenges despite considerable progress and achievements

TL;DR: The recently growing support from international organizations and governments of some endemic countries is warmly welcome and should be optimally exploited in the various approaches to drug and insecticide research and development to overcome the burden of these prevalent diseases, especially malaria, leishmaniasis, Human African Trypanosomiasis, and Chagas disease.
Journal ArticleDOI

Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data

TL;DR: It is demonstrated that in 2006-2007, chloroquine and SP continued to be used at high rates in many African countries and that persistent chloroquin-resistant malaria persists, suggesting that there is continuing use of ineffective anti-malarials in Africa.
Journal ArticleDOI

A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720.

TL;DR: Although the induced anti-MSP2 antibodies did not directly inhibit parasite growth in vitro, IgG from the majority of individuals tested caused significant antibody-dependent cellular inhibition (ADCI) of parasite growth, in view of the reactogenicity of this formulation, further clinical development of M SP2-C1 will require formulation of MSP2 in an alternative adjuvant.
References
More filters
Journal ArticleDOI

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

TL;DR: Artemisinins are potent and rapidly acting antimalarial drugs, and their widespread use for treating patients with Plasmodium falciparum malaria raises the question of emerging drug resistance.
Journal ArticleDOI

Artemisinins target the SERCA of Plasmodium falciparum

TL;DR: It is shown that artemisinins, but not quinine or chloroquine, inhibit the SERCA orthologue (PfATP6) of Plasmodium falciparum in Xenopus oocytes with similar potency to thapsigargin (another sesquiterpene lactone and highly specific SERCA inhibitor).
Journal ArticleDOI

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial.

TL;DR: Artesunate should become the treatment of choice for severe falciparum malaria in adults because it is more rapidly acting than intravenous quinine in terms of parasite clearance and is simpler to administer.
Journal ArticleDOI

Qinghaosu (artemisinin): the price of success.

TL;DR: Artemisinin combination treatments are now first-line drugs for uncomplicated falciparum malaria, but access to ACTs is still limited in most malaria-endemic countries and a global subsidy would make these drugs more affordable and available.
Related Papers (5)

Spread of Artemisinin Resistance in Plasmodium falciparum Malaria

Elizabeth A. Ashley, +82 more